Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

Pre-Hour Stock Surge: Intra-Cellular (ITCI) Rises On Acquisition Agreement

By
Published On January 1, 1970 12:00 AM UTC
Pre-Hour Stock Surge: Intra-Cellular (ITCI) Rises On Acquisition Agreement

Shares of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) are rising on the US stock charts today in response to the takeover move. As of the latest pre-market check, ITCI stock was trading up 34.45% to $127.55.

Expansion of Neuroscience Strategically

Intra-Cellular Therapies (ITCI) and Johnson & Johnson (JNJ) announced their purchase deal. Under the terms of the agreement, JNJ will be able to purchase all of the remaining ITCI shares for $132.00 each in cash, making the deal worth about $14.6 billion. The purchase aligns with Johnson & Johnson’s almost 70-year history of innovation in neuroscience.

JNJ hopes to transform the treatment of neuropsychiatric and neurodegenerative disorders by incorporating intracellular therapies into its Innovative Medicine business. JNJ’s portfolio will be strengthened by ITCI’s primary medication, CAPLYTA (lumateperone), which has been authorized to treat bipolar disorder and schizophrenia.

Promising Future for CAPLYTA

CAPLYTA, characterized by its unique receptor profile, has demonstrated robust efficacy, favorable safety, and tolerability across approved indications. Recent Phase 3 studies revealed its potential as an adjunctive therapy for major depressive disorder (MDD), marking it as a potential first in over 15 years to address both MDD and bipolar-related depressive symptoms. With ongoing trials targeting additional indications, CAPLYTA could redefine treatment standards for mental health disorders.

Transaction Details and Timeline

According to the agreement, JNJ would prioritize research investments and shareholder returns, have a healthy balance sheet, and finance the purchase with a combination of debt and cash reserves. The transaction is anticipated to finalize later this year, subject to regulatory and shareholder clearances.

Because its stock will no longer be listed on the Nasdaq, Intra-Cellular Therapies (ITCI) will become even more integrated into JNJ’s business activities after the acquisition closes. Johnson & Johnson’s dedication to neuroscience innovation is demonstrated by this purchase, which promises improved patient care and long-term benefit for all parties involved.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph